BRII-835 (VIR-2218) + BRII-179 (VBI-2601)

About Brii Biosciences

Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.

Therapeutic Areas

Other Chronic Hepatitis B Drugs